COMMUNIQUÉS West-GlobeNewswire

Avania Strengthens Leadership Team with Appointment of Four New Executives
04/09/2025
BILTHOVEN, Netherlands and BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Avania , the leading global MedTech advisory and clinical development partner, is pleased to announce strategic leadership appointments of four [...]
The Ninth Circuit Orders California to Respond concerning its Mandatory DEI Indoctrination in Continuing Medical Education Courses, According to the Association of American Physicians and Surgeons
04/09/2025
TUCSON, Ariz., Sept. 04, 2025 (GLOBE NEWSWIRE) -- On September 2, the U.S. Court of Appeals for the Ninth Circuit ordered California to respond to a petition for rehearing challenging its diversity, equity, and [...]
Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform
04/09/2025
BioTrack Capital and Yonjin Capital join Series A round alongside other investors including 3E Bioventures Capital, Proxima Ventures Ltd., and Lapam Capital Upsized and over-subscribed Series A total funding of $44 [...]
What’s Really Going On With Federal Funding? SMI and Travis Taylor Lead iC³® Summit Panel Discussion to Deliver Clarity in a Volatile Policy Era
04/09/2025
DALLAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Institutions, and organizations across the life sciences continuum are seeking clarity on how federal research and development (R&D) funding and critical resources can be [...]
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
04/09/2025
The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone. Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 [...]
Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre
04/09/2025
Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de [...]
Inventiva to Participate in Upcoming September Investor Conferences
04/09/2025
Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the [...]
PridCor Therapeutics Reports Positive Long COVID Case Series with Combination Antiviral Regimen
04/09/2025
-New Preprint: PridCor Therapeutics LLC has released a pre-print detailing a case series of 15 patients with Long COVID (LC) who were given a continuous regimen of 120-days of valacyclovir and celecoxib with a pulsed 15 [...]
AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland
04/09/2025
Latest progress from lead program Ampligen for the treatment of pancreatic cancer highlighted at the International 5 th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025); Presentation [...]
Bay Area Lyme Foundation Launches Bay Area Lyme Ventures as First Impact Investment Fund to Support Entrepreneurs and Companies Advancing Lyme Disease Solutions
04/09/2025
New venture philanthropy fund announces initial investments and will help guide game-changing Lyme diagnostics and therapeutics to commercialization PORTOLA VALLEY, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bay Area [...]
Legend Senior Living Welcomes Annalisa Hahn as Senior Vice President of Sales and Marketing
04/09/2025
WICHITA, Kan., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Legend Senior Living, a nationally recognized senior living provider with more than 70 residences across seven states, is pleased to announce the appointment of Annalisa [...]
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur
04/09/2025
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur NANTES, France – 4 septembre 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: [...]
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
04/09/2025
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur
04/09/2025
OSE Immunotherapeutics : une stratégie claire, une gouvernance équilibrée, un cap affirmé vers la création de valeur NANTES, France – 4 septembre 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: [...]
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
04/09/2025
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]
Reverse Stock Split Strengthens HealthLynked’s Market Position as Company Scales AI-Driven Healthcare Platform
04/09/2025
NAPLES, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK ) -- Dear Shareholders, I'm writing to share an important update in the continued evolution of HealthLynked Corp. that reflects [...]
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
04/09/2025
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with [...]
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
04/09/2025
ZUG, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with [...]
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
04/09/2025
MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37 , the leader in expanding patient access to clinical trials, and Catalent ® , a global leader in enabling pharma, biotech, and consumer health partners to [...]

Pages